Decitabine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Decitabine: From Myelodysplastic Syndrome to Refractory Cytopenia of Childhood
One-Sentence Summary
Decitabine is a DNA hypomethylating agent originally developed for myelodysplastic syndrome (MDS) in adults. The TxGNN model predicts it may be effective for Refractory Cytopenia of Childhood — a pediatric MDS subtype — with a prediction score of 99.03%, though currently supported by only 1 publication and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Myelodysplastic syndrome (MDS) — based on known drug class; no German license text available in this evidence pack (not yet marketed) |
| Predicted New Indication | Refractory Cytopenia of Childhood |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L3 (single-center retrospective/observational study; no clinical trials registered) |
| Germany Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, decitabine belongs to the hypomethylating agent (HMA) class — a nucleoside analog that inhibits DNA methyltransferase, restoring normal expression of silenced tumor suppressor and differentiation genes in dysplastic hematopoietic cells. Its efficacy in myelodysplastic syndrome (MDS) has been proven, and mechanistically it may be applicable to refractory cytopenia of childhood.
Refractory cytopenia of childhood (RCC) is classified under the WHO pediatric MDS spectrum and shares core pathophysiology with adult MDS — ineffective hematopoiesis and marrow dysplasia leading to peripheral cytopenias. Given decitabine's established, disease-modifying effect on dysplastic clones in adult MDS, extension of this mechanism to the pediatric RCC population is biologically plausible, particularly as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT), which is already being explored clinically.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35624441 | 2022 | Retrospective study | BMC Pediatrics | Single-center 10-year experience using a decitabine-combined minimally myelosuppressive regimen (DAC+MMR) as a bridge to allo-HSCT in pediatric MDS, reporting outcomes for this treatment approach. |
Germany Market Information
Decitabine is not currently marketed in Germany (未上市); no authorization records are available in this evidence pack.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Hypomethylating agent (cytotoxic nucleoside analog / epigenetic-modifying antineoplastic) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Cytotoxic drug handling regulations apply (hazardous drug) |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting this indication is currently limited to a single retrospective, single-center literature report with no registered clinical trials; the drug is also not yet marketed in Germany and key MOA/safety data are missing, making this insufficient to advance beyond exploratory status.
To proceed, the following is needed:
- TFDA/BfArM package insert data (warnings, contraindications, DDI)
- DrugBank-confirmed mechanism of action (MOA)
- Additional clinical trials or larger multi-center studies specifically in pediatric RCC/MDS
- Confirmation of Germany/Taiwan regulatory and market status for decitabine
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.